ALPS Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-32,516
| Closed | -$190K | – | 1160 |
|
|
2022
Q4 | $190K | Buy |
32,516
+6,319
| +24% | +$33.2K | ﹤0.01% | 1004 |
|
|
2022
Q3 | $176K | Sell |
26,197
-468
| -2% | -$2.84K | ﹤0.01% | 1011 |
|
|
2022
Q2 | $112K | Buy |
+26,665
| New | +$106K | ﹤0.01% | 1025 |
|
|
2021
Q2 | – | Sell |
-55,449
| Closed | -$277K | – | 925 |
|
|
2021
Q1 | $277K | Buy |
55,449
+1,807
| +3% | +$14.6K | ﹤0.01% | 837 |
|
|
2020
Q4 | $678K | Buy |
53,642
+15,801
| +42% | +$180K | 0.01% | 437 |
|
|
2020
Q3 | $372K | Sell |
37,841
-2,614
| -6% | -$25.8K | 0.01% | 496 |
|
|
2020
Q2 | $403K | Sell |
40,455
-11,535
| -22% | -$111K | 0.01% | 483 |
|
|
2020
Q1 | $460K | Buy |
51,990
+3,591
| +7% | +$35.4K | 0.01% | 447 |
|
|
2019
Q4 | $446K | Buy |
48,399
+980
| +2% | +$6.94K | ﹤0.01% | 522 |
|
|
2019
Q3 | $279K | Sell |
47,419
-2,380
| -5% | -$25.3K | ﹤0.01% | 815 |
|
|
2019
Q2 | $598K | Sell |
49,799
-6,791
| -12% | -$73K | ﹤0.01% | 498 |
|
|
2019
Q1 | $683K | Sell |
56,590
-32,029
| -36% | -$472K | ﹤0.01% | 418 |
|
|
2018
Q4 | $1.11M | Buy |
88,619
+11,322
| +15% | +$156K | 0.01% | 285 |
|
|
2018
Q3 | $1.15M | Buy |
77,297
+23,761
| +44% | +$374K | 0.01% | 350 |
|
|
2018
Q2 | $901K | Buy |
53,536
+2,607
| +5% | +$50.6K | 0.01% | 356 |
|
|
2018
Q1 | $1.17M | Buy |
50,929
+25,790
| +103% | +$574K | 0.01% | 283 |
|
|
2017
Q4 | $650K | Buy |
25,139
+2,796
| +13% | +$56.3K | ﹤0.01% | 353 |
|
|
2017
Q3 | $330K | Buy |
22,343
+1,981
| +10% | +$28.7K | ﹤0.01% | 718 |
|
|
2017
Q2 | $284K | Buy |
20,362
+1,200
| +6% | +$17.7K | ﹤0.01% | 726 |
|
|
2017
Q1 | $327K | Sell |
19,162
-2,244
| -10% | -$26.9K | ﹤0.01% | 682 |
|
|
2016
Q4 | $220K | Sell |
21,406
-6,930
| -24% | -$63.3K | ﹤0.01% | 691 |
|
|
2016
Q3 | $286K | Sell |
28,336
-2,874
| -9% | -$31.4K | ﹤0.01% | 646 |
|
|
2016
Q2 | $350K | Buy |
+31,210
| New | +$397K | ﹤0.01% | 544 |
|
|
2016
Q1 | – | Sell |
-25,871
| Closed | -$491K | – | 780 |
|
|
2015
Q4 | $491K | Hold |
25,871
| – | – | ﹤0.01% | 470 |
|
|
2015
Q3 | $4.86K | Buy |
+25,871
| New | +$440K | 0.01% | 450 |
|
ALPS Advisors's CNCE Position: Q1 2023 in Review
ALPS Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 32,516 shares — an estimated $190K sold.
ALPS Advisors first reported a position in CNCE in Q3 2015 and held it in 25 quarters. The position peaked at $1.17M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- ALPS Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- ALPS Advisors sold 32,516 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $190K.
- ALPS Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q3 2015 and held it in 25 quarters.
- ALPS Advisors's Concert Pharmaceuticals, Inc. position peaked at $1.17M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on ALPS Advisors's 13F filing for Q1 2023, filed 10 May 2023.